M Ventures participated in a $28m round completed by Plexium, which is working on small molecule drugs to treat cancer or neurodegenerative diseases.

US-based cancer and neurodegenerative disease therapy developer Plexium has emerged from stealth with $28m in series A funding from investors including M Ventures, a subsidiary of pharmaceutical firm Merck Group. Venture capital firms Data Collective and The Column Group (TCG) co-led the round, the latter through its DCVC Bio vehicle, while fellow VC firms CRV…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.